Beleave Inc buy Subdi
Summary
This prediction ended on 23.10.18 with a price of €0.076. The prediction for Beleave Inc disappointed with a performance of -26.61%. Subdi has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Beleave Inc | - | - | - | - |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% | 65.292% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% | 97.467% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% | 39.755% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% | 61.093% |
Comments by Subdi for this prediction
In the thread Beleave Inc diskutieren
Subdi stimmt der Sell-Einschätzung von ascko nicht zu
Subdi stimmt am 10.07.2017 der Sell-Einschätzung von ascko mit dem Kursziel 0,6€ nicht zu.
Überschrift: ascko stimmt der Buy-Einschätzung von Subdi nicht zu
Beleave Inc. ("Beleave" or the "Company") is a biotech company focused on the production of medical marijuana in Canada. The Company's wholly-owned subsidiary First Access Medical Inc. has received a license to cultivate medical marijuana at its facility pursuant to the Access to Cannabis for Medical Purposes Regulations outlined by Health Canada. The Company is actively working towards its sales license, the development of patents through research with Canadian institutions and the research and development of smoke harm reduction products.
http://thecse.com/en/listings/life-sciences/beleave-inc
... im Gegensatz zu vielen US-Pot-Stocks ist das wenigstens keine Luftnummer, sondern ein junges Unternehmen mit realem Geschäft in einem Wachstumsmarkt. Natürlich spekulativ, aber aus meiner Sicht mit guten Erfolgschancen...
Kauflimit: 0,751€